ADVERSE REACTIONS TO CONTRAST MEDIUM DURING ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY

Abstract

Adverse effects of urografin used in endoscopic retrograde cholangiopancreatography (ERCP) were studied in 20 patients with positive results on the intravascular urografin pretest, and 27 patients with adverse reactions to intravascularly administered contrast media on the past examination and with no urografin pretest (group A), and 139 patients with no adverse reactions at the past and with negative results on the urografin pretest (group B). The incidence of adverse reaction of urografin after endoscopic retrograde cholangiography ('ERC') was extremely low (zero and 3% in group A and B, respectively), while the incidence after endoscopic retrograde pancreatography ('ERP') showed a tendency to be higher in group A (25%) than in group B (5%). After endoscopic retrograde cholangiopancreatography ('ERCP') also, the incidence in group A (22%) was higher than that in group B (1%). There was no patients with severe adverse reaction. The incidences in the groups were considered to be lower than that of adverse reaction observed during excretory urography or intravenous cholangiography. Excretory urograms were also confirmed in some of the patients with 'ERCP' or 'ERP'. It was considered that urografin injected into the pancreatic duct got into the blood vessels via the pancreas and was excreted into the urinary tract. There was no difference in the frequency of ERCP-induced diarrhea between groups A (13%) and B (9%).